AUS
NZ
UK
CA
USA
IND
Highlights:
- Conavi Medical Corp. specializes in cardiovascular imaging technology.
- The company has engaged ICP Securities Inc. to provide automated market making services.
- The agreement between Conavi Medical and ICP starts from October 2024.
Conavi Medical Corp. (TSXV:CNVI) operates within the medical technology sector, specifically focusing on imaging solutions for minimally invasive cardiovascular procedures. These types of procedures are common in modern healthcare, helping to diagnose and treat heart-related conditions without the need for extensive surgery. The development and marketing of advanced imaging technologies have become essential in improving the precision and outcomes of these procedures.
Company’s Core Focus
Conavi Medical's primary focus is on creating innovative imaging systems designed to guide cardiovascular procedures. Their technology assists healthcare professionals by providing real-time images during operations, which can enhance decision-making and patient care. Such systems are critical in today’s healthcare environment, where the need for precision in surgical techniques is increasing.
ICP Securities Inc. Engagement
Conavi Medical recently entered into an agreement with ICP Securities Inc. for automated market making services. ICP is tasked with providing liquidity and improving the trading efficiency of Conavi's shares on the TSX Venture Exchange. The engagement involves the use of ICP’s proprietary algorithm, ICP Premium™, which complies with all relevant TSX Venture Exchange policies and legislation.
ICP's services aim to create a smoother and more consistent trading experience for shareholders, ensuring that Conavi’s stock price better reflects its market demand. Market makers, such as ICP, play a key role in maintaining order within the stock exchange by acting as intermediaries between buyers and sellers.
Details of the Agreement
The engagement between Conavi Medical and ICP will begin on October 22, 2024. The initial term of the agreement is for four months, with the possibility of automatic renewal for subsequent one-month periods unless either party decides to terminate it with written notice. The monthly fee for ICP's services is fixed at C$7,500, which includes all applicable taxes. Importantly, the contract between the two companies does not include performance-related metrics or any form of stock or equity-based compensation.
ICP Securities has indicated that, as of now, it holds no securities of Conavi Medical. However, they have left open the possibility of acquiring shares in the future, which is a standard practice in such agreements.
Strategic Implications
Conavi Medical’s decision to engage ICP comes at a critical time as the company seeks to strengthen its market presence. Automated market making can help enhance liquidity, stabilize share prices, and promote more active trading. These services align with Conavi’s broader objectives of growing its market profile while continuing to focus on its core mission of advancing cardiovascular healthcare technologies.
Conavi’s innovative products, coupled with strategic moves to improve stock liquidity, underscore its commitment to driving progress in medical technology and providing valuable tools for the healthcare industry.
